A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
about
Muscle-invasive urothelial bladder cancer: an update on systemic therapyTargeted therapy in advanced bladder cancer: what have we learned?Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial CarcinomaDovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.Systemic therapy in bladder cancerIncidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysisCisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapyHigh rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: A systematic review and meta-analysis.Ameliorative Effects of Chloroform Fraction of Cocos nucifera L. Husk Fiber Against Cisplatin-induced Toxicity in Rats.Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.New advances in genitourinary cancer: evidence gathered in 2014.Targeted therapies in bladder cancer: an overview of in vivo research.Targeting Signaling Transduction Pathways in Bladder Cancer.Emerging drugs for urothelial (bladder) cancer.Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer.The safety and efficacy of gemcitabine for the treatment of bladder cancer.Systemic therapy for metastatic bladder cancer in 2016 and beyond.Improving Systemic Chemotherapy for Bladder Cancer.Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab).Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer.Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
P2860
Q26775780-8AA1E692-45FC-4946-95BE-28D6E83F1B61Q27009469-99BEFBB1-FE34-4B59-92B7-A35EA4D1A75EQ28084715-3892704E-9973-4FFA-9F12-0E4255E6079AQ30857433-7A6B44A7-EC01-4BEF-AE7A-1703412DE5CCQ33578564-7B207CDC-9BCE-4F55-998A-25E6407A56EAQ34537664-5D699D8E-9914-466B-848C-896EFB4DCD67Q35771672-6FF4E130-8A84-4BD9-8E63-08E044377579Q36042344-75B1B3C5-035A-474A-9AB7-382DF8BB1610Q36657380-CEB532D1-1F08-4C0F-AD56-923EB1E0D330Q37588340-469CE060-9F66-4077-AEE2-21CDA85B87F7Q37609437-BD4C058F-9E88-4CD8-9988-E50F65FF6640Q38557894-22E36F9A-26D2-412E-9B2D-E0F5D82E2145Q38590471-87530270-166E-42E1-B5EA-3D3DCCC31C3DQ38608540-31A9E3DA-359D-4EEF-BE35-D4E6C16BE90FQ38677414-2DC4BDBF-2517-4F61-B724-A3EB33550727Q38679713-A3A79866-C046-483A-9616-78F3071659E2Q38701535-C2D91E57-8CB4-4DA5-94E0-B067A028B3D1Q38753358-58A709C7-7C3C-4C46-ADED-3AEFE2E8835DQ38777610-52FC369C-012A-41AF-9167-745C07DE19FCQ38906609-A1824B7F-C16E-4DF0-B93C-16FC17861BE1Q47965170-DA17CC63-070B-4B0E-99C4-EEAFB9A7803FQ48226075-309DE32B-4FEE-415D-8F24-6440EE9D32D8Q50064748-9FF27174-9ED8-4782-BCCF-D01B76ACA0F6Q55254546-2FC5FCE1-2492-4E6C-94FB-19A201A2CF20
P2860
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A randomized phase 2 trial of ...... advanced urothelial carcinoma.
@ast
A randomized phase 2 trial of ...... advanced urothelial carcinoma.
@en
A randomized phase 2 trial of ...... advanced urothelial carcinoma.
@nl
type
label
A randomized phase 2 trial of ...... advanced urothelial carcinoma.
@ast
A randomized phase 2 trial of ...... advanced urothelial carcinoma.
@en
A randomized phase 2 trial of ...... advanced urothelial carcinoma.
@nl
prefLabel
A randomized phase 2 trial of ...... advanced urothelial carcinoma.
@ast
A randomized phase 2 trial of ...... advanced urothelial carcinoma.
@en
A randomized phase 2 trial of ...... advanced urothelial carcinoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
A randomized phase 2 trial of ...... advanced urothelial carcinoma
@en
P2093
Arlene O Siefker-Radtke
Ellis Glenn Levine
Gary R MacVicar
Kathleen C Day
Maha Hussain
Mahmoud Al-Hawary
Mario A Eisenberger
Mark L Day
Neeraj Agarwal
P2860
P304
P356
10.1002/CNCR.28767
P407
P577
2014-05-06T00:00:00Z